Project Grant R01DK141802
Award Date 9/1/25
Completion Date 8/31/30
Dollars Obligated $724K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Palo Alto, CA 94304, USA
Similar Awards
- This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $199,258 to The Leland Stanford Junior University to conduct research aimed at advancing cell-based therapies for Type 1 Diabetes Mellitus (T1D). The key objectives are to: 1) establish effective, non-toxic strategies to induce immune tolerance toward donor tissues for islet cell...
- This federal Project Grant award of $208,428, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research), aims to enhance the safety and efficacy of stem cell-derived islet transplantation for treating type 1 diabetes. The key objectives are to improve the survival and engraftment of the transplanted cells, enable long-term insulin independence, and develop safety mechanisms to retrieve the graft...
- This $3,140,632 federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research program) aims to elucidate the mechanisms underlying human endocrine lineage commitment and harness this knowledge to improve strategies for beta cell replacement in diabetes treatment. The 4-year project, awarded to the Regents of the University of California, San Francisco, seeks to enhance the...
- This $681,562 Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) aims to investigate approaches for enhancing the metabolic maturity and functionality of human pluripotent stem cell-derived islet organoids, with the goal of improving their survival and efficacy for transplantation as a treatment for type 1 diabetes. The research will examine the use of pharmacological agents...
- This federal Project Grant award of $2,390,830 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847) aims to develop scalable and transplantable pancreatic islet organoids with engineered oxygenation. The 4-year project, awarded on September 1, 2025, will be carried out by the University of California, San Francisco. The research seeks to create an islet-supportive microenvironment to improve islet engraftment efficiency for Type 1 diabetes patients undergoing...
- This Cooperative Agreement award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $1,108,154 to develop a stem cell-based multi-cellular platform that integrates diverse types of immune cells with stem cell-derived islets. The goal is to create an improved preclinical research model to accelerate the development of therapeutic interventions for Type 1...
- This $372,067 Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports the development of an immune evasive stem cell line for type 1 diabetes regenerative therapy. The grant recipient, Aleutian Therapeutics, Inc., a biotechnology company in Los Angeles, California, is conducting research to create gene editing technologies that enable allogeneic...
- This federal Project Grant award of $1,500,424 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), will support research to comprehensively characterize pretransplant operation strategies and local conditions across adult kidney transplant programs in the United States. The goal is to understand how certain pretransplant operation practices can impact patient access,...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $410,449 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to The Leland Stanford Junior University (Stanford University) on August 1, 2025. The funding supports research to develop novel synthetic biology strategies that would enable the quantitative and dynamic regulation of growth factors and cytokines produced from human induced pluripotent stem cell-derived endothelial cells (iPSC-ECs). The goal...
- This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is for the transformation of a human-induced pluripotent stem cell (iPSC)-derived bone marrow organoid to study hematopoiesis. The key objectives are to perform cellular mapping of the organoid, optimize it for the study of hematopoietic development, and culture the organoid under specific...